Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7789 in Advanced Solid Tumors and NSCLC (Japan)
jRCT2031220675Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of sabestomig in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD7789, Treatment discontinuations due to AEs and 1 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
sabestomig
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220675.